...
首页> 外文期刊>British journal of clinical pharmacology >Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index
【24h】

Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index

机译:对不同类型的降压药对臂和收缩期血压及增强指数的比较作用的Meta分析

获取原文

摘要

AIMS Brachial systolic blood pressure (bSBP) exceeds aortic pressure by a variable amount, and estimated central systolic blood pressure (cSBP) may be a better indicator of cardiovascular risk than bSBP. We undertook a systematic review and meta-analysis to compare the effect of single and multiple antihypertensive agents on bSBP, cSBP and augmentation index (AIx).Methods A random effects meta-analysis was performed on 24 randomized controlled trials of antihypertensives with measurements of bSBP, cSBP and/or AIx. Separate analyses were performed for drug comparisons with or without placebo, and drug combinations.Results In the placebo vs. drug meta-analysis, antihypertensive therapy reduced bSBP more than cSBP and there was no statistically significant evidence of heterogeneity by drug class, although the number of individual studies was small. In placebo-adjusted drug vs. drug comparison, treatment with β-blockers, omapatrilat and thiazide diuretics lowered cSBP significantly less than bSBP (i.e. central to brachial amplification decreased), whereas other monotherapies lowered cSBP and bSBP to similar extents. Sample sizes were too small and effect estimates insufficiently precise to allow firm conclusions to be made regarding comparisons between individual drug classes. Antihypertensive combinations that included β-blockers decreased central to brachial amplification. β-Blockers increased AIx, whereas all other antihypertensive agents reduced AIx to similar extents.CONCLUSIONS A reduction in central to brachial amplification by some classes of antihypertensive drug will result in lesser reductions in cSBP despite achievement of target bSBP. This effect could contribute to differences in outcomes in randomized clinical trials when β-blocker- and/or diuretic-based antihypertensive therapy are compared with other regimens.
机译:AIMS肱动脉收缩压(bSBP)超过主动脉压的幅度可变,估计的中央收缩压(cSBP)可能比bSBP更好地指示了心血管风险。我们进行了系统的回顾和荟萃分析,比较了单一和多种降压药对bSBP,cSBP和增强指数(AIx)的影响。方法对24例随机的抗高血压对照试验进行随机荟萃分析,并测量bSBP ,cSBP和/或AIx。结果在安慰剂与药物荟萃分析中,降压治疗对cSBP的抑制作用比对cSBP的抑制作用要大,并且在统计学上没有明显的异质性证据,尽管有个人研究的比例很小。在安慰剂调整后的药物与药物比较中,使用β受体阻滞剂,奥马帕特立和噻嗪利尿剂治疗可使cSBP明显低于bSBP(即中枢至臂间扩增降低),而其他单一疗法则将cSBP和bSBP降低至相似程度。样本量太小,效果评估不够精确,无法就各个药物类别之间的比较得出明确的结论。包含β受体阻滞剂的降压药组合可降低臂丛中枢的扩增。 β-阻滞剂会增加AIx,而所有其他降压药都会使AIx降低至类似程度。结论尽管达到了目标bSBP,某些类别的降压药使肱骨中枢至臂丛的扩增减少,导致cSBP的减少程度较小。当将基于β受体阻滞剂和/或利尿剂的降压治疗与其他方案进行比较时,这种效果可能会导致随机临床试验结果的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号